山东省眼科医院史伟云院长就世界首个SFDA批准的生物工程角膜相关临床问题，接受了哥伦比亚电视台的专访。专访以《Scientists working on restoring human sight with pig eyes》为题在哥伦比亚电视台播出后，引起了极大反响。
  史伟云院长详细介绍了世界首个SFDA批准的生物工程角膜临床应用情况：“生物工程角膜是由异种角膜经脱细胞特殊工艺的多级处理，去除了角膜中的细胞、杂蛋白、多糖等抗原，保留了天然角膜基质胶原蛋白结构及透明性，生物相容性好，生物安全性高，能与周围组织快速整合，移植角膜透明，患者视力快速恢复。这是拥有完整自主知识产权的高科技划时代产品。”
  同时史伟云院长强调：“人工生物角膜与捐献人角膜在移植手术技术上有着明显的特点，不论从手术适应症选择到围手术期处理都有着独特的技巧，因此生物工程角膜移植手术医师培训是角膜盲患者复明的不可或缺的关键因素。”
在山东省眼科医院工作人员的引导下，经过消毒等程序，采访组部分人员获得允许进入手术室对史伟云院长使用组织工程角膜进行角膜移植手术进行拍摄，史伟云院长精湛的手术技术让从事多年医疗采访的哥伦比亚电视台记者十分惊讶，连连称赞：“观看史院长做手术就像在欣赏一场精彩的演出。”
  采访期间，史伟云院长诙谐的说：“你们哥伦比亚电视台因为台标像眼睛，所以在美国也被称作‘眼睛台’，这跟我们眼科有很深的渊源啊。”史院长的诙谐引让采访气氛格外轻松。
  哥伦比亚电视台记者还对已经接受过生物工程角膜移植的患者进行了采访。

  相关资料：
  以山东省眼科研究所、山东省眼科医院谢立信院士和泰山攀登计划特聘专家史伟云教授带领的学术团队是中国再生医学国际公司研发的全球首个生物工程角膜技术支持的主要力量。该生物角膜于2015年4月底获得国家食品药品监督管理总局颁发的医疗器械注册证书，2015年5月23日正式投产上市。作为全球首个生物工程角膜，可广泛应用于50%的角膜盲治疗，将极大地缓解我国捐献角膜奇缺的临床困境，为我国400万乃至全球6000万的角膜盲患者带来复明的希望。2015年9月上市后的世界首例生物工程角膜临床移植在山东省眼科研究所（青岛眼科医院，山东省眼科医院）获得成功。  
  鉴于山东省眼科研究所在角膜研发中的巨大贡献和在全国角膜病基础与临床研究领域的龙头地位，首个生物工程角膜手术医生培训基地已在山东省眼科医院建立。2016年7月至今已培训近300名国内学员，十余位国际学员，培训班使学员们对生物工程角膜有了更加深刻的认识，同时提高了临床实践能力与手术技能，为更好从事角膜病防治工作奠定了理论与实践基础。

史伟云教授简介：

眼科学博士，二级教授、主任医师，博士生导师。中华医学会眼科学分会常委、专家会员，中华医学会眼科学分会角膜病组组长，《中华眼科杂志》副总编辑及其他8个眼科杂志编委。现任山东省眼科研究所党委书记、所长、山东省眼科医院院长。国务院特殊津贴专家、山东省泰山岗位攀登计划特聘专家、省有突出贡献的中青年专家和山东省首届医学领军人才。在临床工作方面，具有丰富的临床经验和娴熟的显微手术技巧，能熟练完成各类眼前段手术，如抗青光眼、白内障超声乳化摘除联合人工晶体植入和各种眼科屈光手术等，尤其在角膜移植术手术方面具有较高的造诣，能够熟练进行各类复杂的角膜移植术，已累计完成近万例。科研教学方面，作为课题负责人或主要人员共承担科研课题 20 余项，获得国家发明专利 4 项。其中作为负责人承担国家 863 重大课题、973 重大专项、国家自然科学基金重点项目和面上项目、山东省自然科学基金及省攻关课题等。发表论文 258 篇、其中 SCI 收录 53 篇，第一和通讯作者在（PNAS、Ophthalmology）等 SCI 收录31篇，人民卫生出版社出版我国首部《角膜手术学》和《角膜病学》学术专著，获国家科技进步二等奖两项和为首获山东省科技进步一等奖两项。
  哥伦比亚电视台简介：

美国哥伦比亚电视台，是美国五大电视台之一，是具有巨大世界影响力的的国际化电视台。缩写为CBS，美国三大全国性商业广播电视网之一。1927年成立。总部设在纽约。1941年，正式开办电视广播，1954年，播出彩色电视。1987年在纽约等城市直接经营电视台5座，中波广播电台6座，调频广播电台7座。另有通过合同关系参加该广播网的电视台 200多座，形成全国性广播电视网。

史伟云院长向哥伦比亚电视台记者介绍生物工程角膜相关情况

史伟云院长精湛的手术技术让从事多年医疗采访的哥伦比亚电视台记者十分惊讶

哥伦比亚电视台记者对已经接受过生物工程角膜移植的患者进行采访

史伟云院长、高华副院长与哥伦比亚电视台专访摄制组合影

President Weiyun SHI of Shandong Eye Hospital Accepted an Exclusive Interview with Columbia Broadcasting System

President Weiyun SHI of Shandong Eye Hospital accepted an exclusive interview with Columbia Broadcasting System on the clinical questions about the world’s first bio-engineered cornea approved by SFDA. The broadcasting of the interview named “Scientists working on restoring human sight with pig eyes” on CBS has drawn a great deal of public attention.

President SHI gave a detailed introduction to the clinical application condition of the world’s first bio-engineered cornea approved by SFDA: “The bioengineered corneas are made from xenogeneic corneas through multilevel processing using decellularized special techniques, which remove antigens in corneas like cells, impure protein and polysaccharide and preserve the structure of natural corneal stromal collagens and their transparency. The biocompatibility is good and the biosecurity is high. They can integrate into the surrounding tissue quickly. With transparent transplanted cornea, the visual acuity of patients can be improved quickly. This is an epoch-making high-tech production with complete independent intellectual property rights.”

At the same time, president SHI stressed: “The characteristics of surgical techniques for transplanting artificial biological cornea and donor cornea are obvious. Both the selection of surgical indications and the treatment during perioperative period need unique techniques, so training surgeons for bio-engineered corneal transplantation is an indispensable step in the way to restore sight for patients with corneal blindness.”

Under the guidance of the staff of Shandong Eye Hospital, several members of the interviewing group were allowed to enter the operating room after the disinfection and other procedures to shoot the cornea transplant surgery with tissue engineering cornea by president SHI. The excellent surgical techniques amazed the CBS reporter, who had conduced medical interviews for many years. “Watching the surgery by president SHI is just like watching a wonderful performance.” She praised again and again.

During the interview, president SHI said humorously: “Sometimes CSB is referred to as ‘Eye Network’ as your logo looks like an eye. You see, CBS and ophthalmology are closely connected.” These words made the interview atmosphere more relaxing.

The CBS reporter also interviewed a patient who had received bio-engineered corneal transplantation.

Relative information：

The academic team led by Academician Lixin XIE and Professor Weiyun SHI of Shandong Eye Institute and Shandong Eye Hospital is the main technical support power for the world’s first bio-engineered cornea developed by China Regenerative Medicine International Limited. The bio-engineered cornea has obtained the Registration Certificate for Medical Device from CFDA at the end of April, 2015 and was officially put into production and market on May, 23, 2015. As the world's first bio-engineered cornea, it can be widely used in 50% of corneal blind treatment, which can greatly alleviate the clinical situation of low cornea donation rate in China, and bring hope of regaining sight for 4 million corneal blind patients in China and even 60 million all over the world. The world's first bioengineered corneal clinical transplantation conducted at Shandong Eye Institute (Qingdao Eye Institute, Shandong Eye Hospital) in September 2015 was successful.

In view of the great contributions Shandong Eye Institute has made in the research and development of cornea and its leading role in the basic and clinical researches of corneal disease in China, the first doctor training base for bio-engineered corneal transplantation was established at Shandong Eye Hospital. Since July 2016, nearly 300 domestic doctors and over 10 international doctors have been trained here. The training has helped the doctors to establish a deeper understanding towards bio-engineered cornea and has improved doctors’ clinical practical ability and surgical techniques.